X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GLENMARK PHARMA JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
 
P/E (TTM) x 27.4 12.0 229.1% View Chart
P/BV x 5.6 3.2 178.1% View Chart
Dividend Yield % 0.3 0.4 84.6%  

Financials

 JUBILANT LIFE SCIENCES   GLENMARK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
GLENMARK PHARMA
Mar-17
JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs187993 18.8%   
Low Rs65729 8.9%   
Sales per share (Unadj.) Rs364.3325.5 111.9%  
Earnings per share (Unadj.) Rs6.839.3 17.4%  
Cash flow per share (Unadj.) Rs24.548.7 50.3%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %2.40.2 1,025.6%  
Book value per share (Unadj.) Rs164.9159.2 103.6%  
Shares outstanding (eoy) m159.28282.17 56.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.6 13.1%   
Avg P/E ratio x18.421.9 83.9%  
P/CF ratio (eoy) x5.117.7 29.1%  
Price / Book Value ratio x0.85.4 14.1%  
Dividend payout %43.85.1 861.0%   
Avg Mkt Cap Rs m20,061242,991 8.3%   
No. of employees `0006.213.0 47.7%   
Total wages/salary Rs m11,05216,408 67.4%   
Avg. sales/employee Rs Th9,383.07,083.9 132.5%   
Avg. wages/employee Rs Th1,786.91,265.4 141.2%   
Avg. net profit/employee Rs Th176.3855.1 20.6%   
INCOME DATA
Net Sales Rs m58,03491,857 63.2%  
Other income Rs m191374 51.0%   
Total revenues Rs m58,22492,230 63.1%   
Gross profit Rs m5,78620,367 28.4%  
Depreciation Rs m2,8122,644 106.4%   
Interest Rs m3,2372,373 136.4%   
Profit before tax Rs m-7215,724 -0.5%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,145-810 -265.0%   
Tax Rs m6963,827 18.2%   
Profit after tax Rs m1,09011,088 9.8%  
Gross profit margin %10.022.2 45.0%  
Effective tax rate %-965.924.3 -3,968.7%   
Net profit margin %1.912.1 15.6%  
BALANCE SHEET DATA
Current assets Rs m29,28068,746 42.6%   
Current liabilities Rs m38,91227,027 144.0%   
Net working cap to sales %-16.645.4 -36.5%  
Current ratio x0.82.5 29.6%  
Inventory Days Days8485 99.3%  
Debtors Days Days5196 53.1%  
Net fixed assets Rs m55,71224,132 230.9%   
Share capital Rs m155282 54.7%   
"Free" reserves Rs m20,96844,643 47.0%   
Net worth Rs m26,26544,925 58.5%   
Long term debt Rs m17,16945,363 37.8%   
Total assets Rs m88,606117,639 75.3%  
Interest coverage x1.07.6 12.8%   
Debt to equity ratio x0.71.0 64.7%  
Sales to assets ratio x0.70.8 83.9%   
Return on assets %4.911.4 42.7%  
Return on equity %4.224.7 16.8%  
Return on capital %11.619.1 60.4%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00456,152 39.2%   
Fx outflow Rs m11,7498,084 145.3%   
Net fx Rs m10,25548,068 21.3%   
CASH FLOW
From Operations Rs m8,0266,574 122.1%  
From Investments Rs m-1,744-7,124 24.5%  
From Financial Activity Rs m-4,4475,432 -81.9%  
Net Cashflow Rs m1,8341,992 92.1%  

Share Holding

Indian Promoters % 45.6 48.3 94.4%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 6.9 126.1%  
FIIs % 21.2 34.4 61.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 56,727 42.0%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT LTD.  VENUS REMEDIES  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 19, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - PLETHICO PHARMA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS